Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes

Research output: Contribution to journalReviewResearchpeer-review

  1. Various Leisure-Time Physical Activities Associated With Widely Divergent Life Expectancies: The Copenhagen City Heart Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. MyD88 and TLR4 Expression in Epithelial Ovarian Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Type 2 diabetes is a disease involving both inadequate insulin levels and increased glucagon levels. While glucagon and insulin work together to achieve optimal plasma glucose concentrations in healthy individuals, the usual regulatory balance between these 2 critical pancreatic hormones is awry in patients with diabetes. Although clinical discussion often focuses on the role of insulin, glucagon is equally important in understanding type 2 diabetes. Furthermore, an awareness of the role of glucagon is essential to appreciate differences in the mechanisms of action of various classes of glucose-lowering therapies. Newer drug classes such as dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists improve glycemic control, in part, by affecting glucagon levels. This review provides an overview of the effect of glucose-lowering therapies on glucagon on the basis of an extensive PubMed literature search to identify clinical studies of glucose-lowering therapies in type 2 diabetes that included assessment of glucagon. Clinical practice currently benefits from available therapies that impact the glucagon regulatory pathway. As clinicians look to the future, improved treatment strategies are likely to emerge that will either use currently available therapies whose mechanisms of action complement each other or take advantage of new therapies based on an improved understanding of glucagon pathophysiology.

Original languageEnglish
JournalMayo Clinic Proceedings
Issue number2
Pages (from-to)217-239
Number of pages22
Publication statusPublished - 1 Feb 2018

    Research areas

  • Journal Article, Review

ID: 52367629